Stugeron, tablets 25 mg 50 pcs

Pharmacodynamics

A class IV selective calcium channel blocker. Improves cerebral, coronary and peripheral blood circulation; improves microcirculation.

Inhibiting entry of calcium ions into vascular smooth muscle cells, reduces smooth muscle tone of arterioles, decreases their sensitivity to biogenic vasoconstrictors (adrenaline, noradrenaline), bradykinin. It reduces the excitability of the vestibular apparatus. It is characterized by high tropism to the cerebral vessels. It improves microcirculation by increasing red blood cell deformability and decreasing high blood viscosity. It has moderate antihistamine activity.

Pharmacokinetics

Intake

After oral administration the C max of cinnarizine in plasma is noted after 1-3 hours.

Distribution

The binding to plasma proteins is 91%.

Metabolism

Cinnarizine is completely metabolized.

Elimination

The T 1/2 is 4 hrs. It is excreted as metabolites: 1/3 by the kidneys, 2/3 – through the intestine.

< br>.

Indications

Treatment and prevention of cerebrovascular accidents: cerebral atherosclerosis, conditions after strokes, traumatic brain injuries, discirculatory encephalopathy;
labyrinthine disorders (for maintenance therapy for dizziness, tinnitus, nystagmus, nausea, vomiting);
prevention of kinetosis;
migraine prevention;
treatment and prevention of peripheral circulatory disorders: Raynaud’s disease and syndrome; acrocyanosis, intermittent claudication, trophic disorders, trophic and varicose ulcers, diabetic angiopathy, paresthesia, microcirculation disorders;
as part of complex therapy in the following cases: rapid mental fatigue, irritability, low mood, memory impairment and ability to concentrate.

Pharmacological effect

Pharmacodynamics

Selective class IV calcium channel blocker. Improves cerebral, coronary and peripheral blood circulation; improves microcirculation.

By inhibiting the entry of calcium ions into smooth muscle cells of blood vessels, it reduces the tone of the smooth muscle membrane of arterioles; reduces their sensitivity to biogenic vasoconstrictor substances (adrenaline, norepinephrine), bradykinin. Reduces the excitability of the vestibular apparatus. It is characterized by high tropism for cerebral vessels. Improves microcirculation, increasing the deformability of red blood cells and reducing high blood viscosity. Has moderate antihistamine activity.

Pharmacokinetics

Suction

After oral administration, Cmax of cinnarizine in plasma is observed after 1-3 hours.

Distribution

Plasma protein binding is 91%.

Metabolism

Cinnarizine is completely metabolized.

Removal

T1/2 is 4 hours. Excreted in the form of metabolites: 1/3 – by the kidneys, 2/3 – through the intestines.

Special instructions

In Parkinson’s disease, Stugeron is prescribed only in exceptional cases when the expected benefit significantly outweighs the potential risk.

Stugeron, due to the presence of an antihistamine effect, can neutralize positive reactions during skin diagnostic tests. In this regard, the drug should be discontinued 4 days before testing.

Patients taking the drug are prohibited from drinking alcohol.

Control of laboratory parameters

With long-term use of Stugeron, monitoring of laboratory blood parameters and liver and kidney function parameters is recommended.

Impact on the ability to drive vehicles and other mechanisms that require increased concentration

Patients taking the drug should be careful when engaging in activities that require increased attention and speed of psychomotor reactions.

Active ingredient

Cinnarizine

Composition

1 tablet contains:

Active substances:

cinnarizine – 25 mg.

Excipients:

colloidal silicon dioxide,

potato starch,

magnesium stearate,

povidone,

talc,

corn starch,

lactose monohydrate.

Pregnancy

Despite the fact that animal studies have not established the teratogenic effect of Stugeron, the use of the drug during pregnancy is possible only in exceptional cases when the expected benefit to the mother significantly outweighs the potential risk to the fetus.

It is not known whether cinnarizine is excreted in breast milk, therefore the use of Stugeron during lactation (breastfeeding) is not recommended.

Contraindications

Hypersensitivity to the drug. Erythematous lupus.

Side Effects

From the digestive system: dyspepsia, dry mouth; in isolated cases – cholestatic jaundice.

From the side of the central nervous system: rarely – headache; in elderly patients with long-term use of Stugeron, extrapyramidal syndromes and depression are possible (in such cases, treatment should be interrupted).

Other: allergic reactions, weight gain, increased sweating; in isolated cases – lupus-like syndrome, lichen planus.

Interaction

With the combined use of Stugeron and ethanol (or ethanol-containing drugs), antihypertensives, nootropic and vasodilators, and other drugs that have a depressant effect on the central nervous system (tricyclic antidepressants, hypnotics, sedatives), an increase in their effect is noted.

Overdose

Symptoms: vomiting, drowsiness, tremor, arterial hypotension, coma.

Treatment: gastric lavage, administration of activated carbon; carry out symptomatic therapy. There is no specific antidote.

Storage conditions

Store in a dry place, protected from light, at a temperature of 15° to 30°C.

Shelf life

5 years.

Manufacturer

Gedeon Richter, Hungary